Emerald Health Therapeutics Inc (CVE: EMH)

Emerald Health Therapeutics Inc is a Canadian pharmaceutical company focusing on medical marijuana products. It is considered as British Columbia’s first publicly traded medical marijuana company. The company primarily operates through its subsidiary Thunderbird Biomedical Inc. This subsidiary is one of the first companies in Canada to obtain a medical marijuana production license under the country’s Marihuana for Medical Purposes Regulations (MMPR).

Currently, Emerald Health Therapeutics’s portfolio comprises of more than 60 strains of high-grade premium medicinal marijuana. This includes well-known strains like Pink Kush, Blue God, and Island Honey.

Through Thunderbird Biomedical, Emerald Health Therapeutics has its alpha facility in Saanich, Victoria, British Columbia. The facility, covering 3,178 square feet, has been licensed by Health Canada to produce and sell 243 kg of dried marijuana. This makes Thunderbird Biomedical the fifth company in the country to get such a license.

The company’s second facility is also located in Victoria, BC. It has a floor space of 28,966 square feet, with an option for a 14,500-square feet mezzanine space, totaling to 43,500 square feet. Thunderbird has started infrastructure work in it and aims to have it inspected by Health Canada in the first quarter of 2015.

Emerald Health Therapeutics Inc was founded in 2007 as Firebird Capital Partners. It operated as Firebird Energy, Inc, which explored and developed oil and natural gas properties in Western Canada. In August 2014, it became T-Bird Pharma Inc following a reverse takeover.

The company now trades in the TSX Venture Exchange as TPI, with a market cap of CAD 6.95 M. Its management team includes Robert Gagnon, Founder and CEO; Rick Morris, VP of Operations; Chris Taylor, CFO; and Karen Parent, VP of Quality Assurance.

[hungryfeed max_items=”5″ template=”1″ url=”feed://feeds.finance.yahoo.com/rss/2.0/headline?s=TPI.V&region=US&lang=en-US”]